Through our culture of collaboration, connectivity and data-based science, MD Anderson experts have set the standard for how immunotherapy is used to treat patients with cancer across the globe. Our faculty are working to bring the benefits of immunotherapy to even more patients by integrating immunobiology across all cancer disciplines. MD Anderson’s unique environment and vast resources allow researchers to accelerate novel discoveries into practice-changing therapies that propel us closer to our goal: a world free of cancer.
At the 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting, our experts are showcasing pacesetting research and joining colleagues for discussion on the latest science, development and application of immunotherapy.
Below are highlights from our presentations, details about onsite networking opportunities with our experts, and information on our open positions for faculty and trainees.
Featured News
Meet the Experts
Visit MD Anderson at Booth 1027 to network with us, ask a question, learn about training and career opportunities and continue the conversation on key presentations with our experts. Check back for the updated Meet the Experts schedule soon.
Exhibit Hall Hours
Friday, Nov. 8: 9 a.m.–7 p.m.
Saturday, Nov. 9: 9 a.m.–8:30 p.m.
Barista-crafted coffee available at the booth during all hours of the exhibit hall.
Friday, November 8
10–10:30 a.m.
Phase I Clinical Trials: The Foundation of Cancer Drugs
Stéphane Champiat, M.D., Ph.D.
Associate Professor, Investigational Cancer Therapeutics
Jennifer Litton, M.D.
Vice President, Clinical Research
Professor, Breast Medical Oncology
Aung Naing, M.D.
Professor, Investigational Cancer Therapeutics
10:30–11 a.m.
CAR T Cells and T Cell Bispecifics for Hematologic Malignancies
Samer Srour, M.B.Ch.B.
Assistant Professor, Stem Cell Transplantation
11–11:30 a.m.
Immunotherapy for Prostate Cancer: What's New?
Bilal Siddiqui, M.D.
Assistant Professor, Genitourinary Medical Oncology
Sumit Subudhi, M.D., Ph.D.
Associate Professor, Genitourinary Medical Oncology
11:30 a.m.–12 p.m.
Learning from Our Patients: Translational Molecular Pathology
Cara Haymaker, Ph.D.
Associate Professor, Translational Molecular Pathology
Humam Kadara, Ph.D.
Professor, Translational Molecular Pathology
2–2:30 p.m.
Managing Immune Checkpoint Inhibitor Side Effects
Yinghong "Mimi" Wang, M.D., Ph.D.
Professor, Gastroenterology, Hepatology and Nutrition
5:30–6 p.m.
Institute for Cell Therapy Discovery & Innovation
Katy Rezvani, M.D., Ph.D.
Professor, Stem Cell Transplantation
Saturday, November 9
9–9:30 a.m.
Cold to Hot: Transforming Tumors for Improved Outcomes
Xi Chen, Ph.D.
Associate Professor, Experimental Therapeutics
Michael Curran, Ph.D.
Professor, Immunology
10–10:30 a.m.
Advances in Thoracic Cancer and Immunology
Marcelo Negrao, M.D.
Assistant Professor, Thoracic Medical Oncology
Stephanie Schmidt, Ph.D.
Data Science Group Leader, Genomic Medicine
10–10:30 a.m.
The James P. Allison Institute
James Allison, Ph.D.
Founding Director, James P. Allison Institute
Regental Professor and Chair, Immunology
Padmanee Sharma, M.D., Ph.D.
Director of Scientific Programs, Allison Institute
Professor, Genitourinary Medical Oncology and Immunology
10:30–11:30 a.m.
The Postdoctoral Experience at MD Anderson
Mehdi Chaib, Ph.D.
Odyssey Fellow
Cara Haymaker, Ph.D.
Associate Professor, Translational Molecular Pathology
Alexander Lazar, M.D., Ph.D.
Professor, Pathology
Golnaz Morad, D.D.S., Ph.D.
NIH/NCI Ruth Kirschstein Postdoctoral Fellow
Elise Nassif Haddad, M.D., Ph.D.
Assistant Professor, Sarcoma Medical Oncology
Jacqueline Oliva Ramirez, Ph.D.
Postdoctoral Fellow, Translational Molecular Pathology
11:30 a.m.–12 p.m.
Our Culture of Team Science
Giulio Draetta, M.D., Ph.D.
Senior Vice President and Chief Scientific Officer
Eyal Gottlieb, Ph.D.
Vice President of Research
Tim Heffernan, Ph.D.
Vice President, Head of Oncology Research, Therapeutics Discovery Division
Timothy Yap, M.B.B.S., Ph.D.
Professor, Investigational Cancer Therapeutics
11:30 a.m.–12 p.m.
Innovations in Vaccine Research
Adam Grippin, M.D., Ph.D.
Resident Physician, Radiation Oncology
Eduardo Vilar-Sanchez, M.D., Ph.D.
Department Chair ad interim, Clinical Cancer Prevention
12:30–1 p.m.
Institute for Data Science in Oncology
Linghua Wang, M.D., Ph.D.
Associate Professor, Genomic Medicine
Jia Wu, Ph.D.
Associate Professor, Imaging Physics
5–5:30 p.m.
The Latest in Melanoma Treatment
Isabella Glitza Oliva, M.D., Ph.D.
Professor, Melanoma Medical Oncology
Our research by the numbers
$1.2B
invested in research
1,568
clinical trials
90
patents awarded
From Sept. 1, 2022 to Aug. 31, 2023
Education and Training at MD Anderson
MD Anderson academic programs are competitive and comprehensive. We offer educational opportunities from undergraduate degrees to graduate medical education opportunities.
Why Houston?
As America's fourth-largest city, Houston has a lot to offer. Find out why Houston is a hub for scientific and medical excellence.
Institutes at MD Anderson
United by a shared mission to end cancer, MD Anderson clinicians and scientists work seamlessly together to advance groundbreaking research that can transform the field of immunotherapy. Leveraging our unique research ecosystem, including three leading institutes, we are pioneering new prevention, diagnostic and treatment approaches to address the most pressing needs for patients with cancer.
James P. Allison Institute
The James P. Allison Institute is dedicated to advancing exceptional discovery, translational and clinical research to integrate immunobiology across disciplines and unlock the full potential of science and medicine for human health. The institute builds upon the legacy of its namesake, James P. Allison, Ph.D., who was awarded the 2018 Nobel Prize in Physiology or Medicine for his fundamental discoveries in T cell biology and his invention of ipilimumab, the first immune checkpoint inhibitor to treat cancer.
Institute for Cell Therapy Discovery & Innovation
Building upon unparalleled expertise, MD Anderson’s Institute for Cell Therapy Discovery & Innovation is leading the world in developing and advancing impactful cell therapies for patients in need. By uniting the top minds in the field to lead exceptional fundamental, translational and clinical research, we're focused on creating breakthrough off-the-shelf therapies that can be readily adapted for both hematologic and solid tumors as well as devastating auto-immune conditions, infections and other diseases.
Learn more about the Institute for Cell Therapy Discovery & Innovation
Institute for Data Science in Oncology
The Institute for Data Science in Oncology (IDSO) integrates the tremendous power of meaningful data extraction and interpretation with MD Anderson’s unparalleled scientific and clinical expertise to transform research and care to impact patients.